143 related articles for article (PubMed ID: 37648063)
1. Presentation, Diagnostic Testing and Initial Treatment of Vitreoretinal Lymphoma.
International Vitreoretinal B-Cell Lymphoma Registry Investigator Group
Ophthalmol Retina; 2024 Jan; 8(1):72-80. PubMed ID: 37648063
[TBL] [Abstract][Full Text] [Related]
2. Vitreoretinal presentation of secondary large B-cell lymphoma in patients with systemic lymphoma.
Salomão DR; Pulido JS; Johnston PB; Canal-Fontcuberta I; Feldman AL
JAMA Ophthalmol; 2013 Sep; 131(9):1151-8. PubMed ID: 23744124
[TBL] [Abstract][Full Text] [Related]
3. Tumor Control and Visual Acuity Outcomes in Vitreoretinal Lymphoma with and without Sub-Retinal Pigment Epithelium Infiltration: Analysis of 125 Eyes of 70 Patients at a Single Ocular Oncology Center.
Dalvin LA; Lim LS; Ancona-Lezama D; Mazloumi M; Chang M; Mashayekhi A; Shields CL
Ophthalmol Retina; 2019 Nov; 3(11):998-1005. PubMed ID: 31358444
[TBL] [Abstract][Full Text] [Related]
4. Aqueous Humor-Derived MYD88 L265P Mutation Analysis in Vitreoretinal Lymphoma: A Potential Less Invasive Method for Diagnosis and Treatment Response Assessment.
Demirci H; Rao RC; Elner VM; Demirci FY; Axenov L; Betz B; Behdad A; Brown N
Ophthalmol Retina; 2023 Feb; 7(2):189-195. PubMed ID: 35952929
[TBL] [Abstract][Full Text] [Related]
5. Diagnostic testing and treatment choices in primary vitreoretinal lymphoma.
Rajagopal R; Harbour JW
Retina; 2011 Mar; 31(3):435-40. PubMed ID: 21336066
[TBL] [Abstract][Full Text] [Related]
6. Prognosis, Risk Factors, and Clinical Features of Intraocular Recurrence in Primary Vitreoretinal Lymphoma.
Liu S; Jiang T; Gu J; Zhou X; Chen W; Ping B; Zhou Y; Zhang T; Huang X; Xu G; Chang Q
Ophthalmol Retina; 2024 Apr; 8(4):317-324. PubMed ID: 37918656
[TBL] [Abstract][Full Text] [Related]
7. Vitreoretinal lymphoma: a 20-year review of incidence, clinical and cytologic features, treatment, and outcomes.
Levasseur SD; Wittenberg LA; White VA
JAMA Ophthalmol; 2013 Jan; 131(1):50-5. PubMed ID: 23307208
[TBL] [Abstract][Full Text] [Related]
8. Characteristics of Vitreoretinal Lymphoma in B-Scan Ultrasonography: A Case-Control Study.
Gu J; Chen Q; Zhang P; Zhang T; Zhou X; Zhang K; Jiang T; Liu S; Chen W; Zhou M; Jiang R; Huang X; Xu G; Chang Q
Ophthalmol Retina; 2024 Mar; 8(3):264-269. PubMed ID: 37820767
[TBL] [Abstract][Full Text] [Related]
9. Vitreoretinal lymphoma: changing trends in diagnosis and local treatment modalities at a single institution.
Turaka K; Bryan JS; De Souza S; Gordon AJ; Kwong HM; Ziemianski MC; Reddy R; Sell CH
Clin Lymphoma Myeloma Leuk; 2012 Dec; 12(6):412-7. PubMed ID: 22995952
[TBL] [Abstract][Full Text] [Related]
10. Clinical Characteristics of Primary Vitreoretinal Lymphoma in an Indian Population.
Mahajan S; Nijhawan R; Rajwanshi A; Karkhur S; Mulkutar S; Dogra M; Lal V; Gupta V; Gupta A
Ocul Immunol Inflamm; 2017 Oct; 25(5):633-638. PubMed ID: 27003620
[TBL] [Abstract][Full Text] [Related]
11. A proposed protocol of intravitreal injection of methotrexate for treatment of primary vitreoretinal lymphoma.
Zhou N; Xu X; Liu Y; Wang Y; Wei W
Eye (Lond); 2022 Jul; 36(7):1448-1455. PubMed ID: 34211136
[TBL] [Abstract][Full Text] [Related]
12. Intraocular lymphoma: a clinical perspective.
Davis JL
Eye (Lond); 2013 Feb; 27(2):153-62. PubMed ID: 23196650
[TBL] [Abstract][Full Text] [Related]
13. Intravitreal rituximab monotherapy for management of eyes with vitreoretinal lymphoma: initial experience from India.
Rishi P; Manchegowda PT; Gondhale HP; Rishi E; Das K; Krishnakumar S; Raja T; Biswas J
Int Ophthalmol; 2021 Jul; 41(7):2495-2504. PubMed ID: 33730314
[TBL] [Abstract][Full Text] [Related]
14. CLINICAL FEATURES, DIAGNOSTIC SIGNIFICANCE, AND PROGNOSIS OF VITREORETINAL LYMPHOMA IN YOUNG PATIENTS.
Liu S; Gu J; Zhang T; Ping B; Zhou M; Huang X; Jiang R; Xu G; Chang Q
Retina; 2021 Dec; 41(12):2596-2604. PubMed ID: 34173362
[TBL] [Abstract][Full Text] [Related]
15. Intraocular-central nervous system lymphoma: clinical features, diagnosis, and outcomes.
Akpek EK; Ahmed I; Hochberg FH; Soheilian M; Dryja TP; Jakobiec FA; Foster CS
Ophthalmology; 1999 Sep; 106(9):1805-10. PubMed ID: 10485554
[TBL] [Abstract][Full Text] [Related]
16. How we diagnose and treat vitreoretinal lymphoma.
Fend F; Ferreri AJ; Coupland SE
Br J Haematol; 2016 Jun; 173(5):680-92. PubMed ID: 27133587
[TBL] [Abstract][Full Text] [Related]
17. Retinal changes of primary vitreoretinal lymphoma after intravitreal methotrexate.
Jiang T; Gu J; Liu S; Chang Q
BMC Ophthalmol; 2022 Sep; 22(1):375. PubMed ID: 36127675
[TBL] [Abstract][Full Text] [Related]
18. Combined treatment of primary vitreoretinal lymphomas significantly prolongs the time to first relapse.
Klimova A; Heissigerova J; Rihova E; Brichova M; Pytlik R; Spicka I; Mrazova K; Karolova J; Svozilkova P
Br J Ophthalmol; 2018 Nov; 102(11):1579-1585. PubMed ID: 29378728
[TBL] [Abstract][Full Text] [Related]
19. Association between ocular findings and preventive therapy with onset of central nervous system involvement in patients with primary vitreoretinal lymphoma.
Hashida N; Nakai K; Saitoh N; Nishida K
Graefes Arch Clin Exp Ophthalmol; 2014 Apr; 252(4):687-93. PubMed ID: 24549401
[TBL] [Abstract][Full Text] [Related]
20. INTRAVITREAL MELPHALAN INJECTION AS A SECOND-LINE LOCAL THERAPY IN VITREORETINAL LYMPHOMA: Case Series.
Guneri Beser B; Demirci H
Retina; 2024 Feb; 44(2):353-359. PubMed ID: 37883576
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
